Casenlax

Quick links to important sections

Casenlax

Method of action: Laxative

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Casenlax

The foundational identity of the medicine Casenlax is rooted in its composition and mechanism, establishing it as a highly specific tool for managing digestive discomfort.

Property Description
Active ingredient Macrogol 4000 (Polyethylene Glycol)
Form Powder for Oral Solution (Sachet)
Pharmacological class Osmotic Laxative
Common use Relief of difficulty passing stools
Origin Synthetic polymer

Defining Casenlax: Class and Identity

Casenlax is the Trade Name for a medicinal preparation whose sole Active Ingredient is Macrogol 4000, a high-molecular-weight synthetic polymer also known as Polyethylene Glycol. It is classified as an Osmotic Laxative, meaning it works by a physical principle within the bowel rather than by stimulating intestinal muscle contraction. This classification reflects its reliable osmotic effect across relevant patient populations. Macrogol is a well-tolerated first-line option for symptomatic management of chronic constipation, indicating the medicine is primarily intended to provide gentle relief from the common issue of hard, infrequent stools.

Composition and Form: Macrogol 4000

The active ingredient is supplied as a Powder for Oral Solution in sachets, designed to be dissolved in water and taken via the Oral Route of Administration. As a single-ingredient product, it contains the biologically inert Macrogol polymer. A key characteristic of this substance is that it undergoes neither significant absorption nor biotransformation within the digestive tract, ensuring its action is strictly local and mechanical. The formulation is often neutral, allowing it to be mixed easily into any non-carbonated drink, aiding patient compliance.

General Purpose: How Osmotic Action Helps

The core function of Casenlax is Osmotic Water Retention. When consumed, the Macrogol polymer attracts and binds water molecules in the intestinal lumen. This retention increases the water content and volume of the stool mass, effectively achieving Stool Softening. This mechanism helps support the body's natural waste transit process, distinguishing it from stimulant types. The overall benefit is the relief of discomfort and difficulty associated with passing hard stools, allowing for a return to regular bowel function.

What side effects are possible with Casenlax?

Possible Side Effects and Safety Information

The official safety profile for Casenlax, which contains Macrogol 4000, is dominated by Gastrointestinal disorders due to the substance's localized osmotic action, as classified in regulatory documents.


Documented Adverse Reactions

The most commonly listed adverse reactions, based on frequency classifications found in official product information, occur within the digestive system:

  • Common (may affect up to 1 in 10 people): Abdominal pain, Diarrhoea, Abdominal distension (bloating), and Nausea.
  • Uncommon (may affect up to 1 in 100 people): Vomiting, Urgency to defecate, and Faecal incontinence.

Reactions affecting the Skin and subcutaneous tissue, such as Pruritus (itching) and Rash, have also been documented. These gastrointestinal effects are noted in regulatory documents as generally transient and often respond to a temporary reduction in the daily amount.


Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions are documented as very rare and include Anaphylactic shock and other severe hypersensitivity reactions (e.g., Angioedema). There is also a documented risk of electrolyte disturbances (like hyponatraemia) and subsequent dehydration, particularly if excessive fluid loss occurs. Official labeling notes that older adults may have an increased susceptibility to these electrolyte disturbances.

The use of Casenlax is subject to regulatory contraindications. It must not be used in individuals with known hypersensitivity to Macrogol, or in the presence of pre-existing severe bowel conditions such as intestinal obstruction (ileus), toxic megacolon, or perforation of the digestive tract or risk of perforation, as these conditions present safety risks.

Overdose and Emergency Response

Overdose and When to Seek Help

Casenlax overdose is defined by the consequences of the product’s excessive osmotic action in the bowel, resulting from overconsumption or abuse. Documented clinical manifestations of overdose include severe, persistent diarrhoea, along with abdominal pain, abdominal distention, and vomiting.

The life-threatening risk associated with severe overdose stems from excessive fluid loss, which can rapidly lead to systemic complications. Regulatory documents emphasize the potential for significant dehydration and subsequent severe electrolyte disturbances. In rare cases, these imbalances may progress to secondary neurological manifestations, such as confusion or seizures. The risk of dehydration and electrolyte imbalance is a heightened concern in children following excessive fluid loss.

Immediate medical action is mandated in the event of a suspected overdose. The official labeling instructs patients to seek urgent medical help and to contact a Poison Control Center right away. Furthermore, immediate help must be sought if signs of severe allergic reaction, such as facial swelling or difficulty breathing, occur.

Management of overdose is officially described as entirely symptomatic and supportive. Treatment involves the close monitoring of fluid status and laboratory parameters, with the main procedural focus on correcting the severe fluid and electrolyte disturbances. The regulatory profile explicitly states that no specific antidote is known for Macrogol 4000 overdose. In mild cases, the required action is simply to reduce the dose or temporarily interrupt treatment.

Therapeutic Uses of Casenlax

What Casenlax Treats: Main Uses and Benefits

Casenlax is commonly used to help manage the symptomatic manifestations of chronic and occasional constipation, addressing conditions characterized by periods of heightened symptoms of slow bowel transit. This medication is applied in situations involving certain distressing symptoms that interfere with daily functioning. This medication is a preferred agent for chronic constipation.

The therapeutic application of Casenlax is considered relevant for easing challenging symptoms, including straining at stool, the passage of hard, dry, or lumpy stools, and a reduced frequency of bowel movements. It is generally used for the symptomatic treatment of constipation in both adults and older adults, and is considered relevant in the clinical scenario of fecal impaction management. This supportive relief helps patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Symptoms of Straining

Casenlax may assist with supporting stool softening, which helps address symptoms related to physical discomfort during bowel movements.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

The eligibility for Casenlax is strictly governed by regulatory status, primarily concerning age and the integrity of the gastrointestinal (GI) tract. Use is generally approved for adults and children aged 8 years and above.

Contraindicated Populations

The medicine must not be used by individuals with:

  • Hypersensitivity to Macrogol 4000 or any excipients.
  • Existing severe GI diseases, including Severe Inflammatory Bowel Disease (such as Ulcerative Colitis or Crohn’s disease) or toxic megacolon.
  • Confirmed or suspected intestinal obstruction, ileus, or perforation of the digestive tract.
  • Acute abdominal pain of unknown cause.

Restricted and Conditional Use

Population Status Eligibility Rule (Regulatory Statement)
Pediatric Use Approved for children ge 8 years, but treatment should not exceed 3 months due to limited long-term data. Not recommended for children under 8 years.
Pregnancy/Lactation Can be used during both pregnancy and breastfeeding, as systemic absorption is negligible.
Comorbid Conditions Caution is required for elderly patients and those with impaired hepatic or renal function if diarrhea occurs, due to the risk of electrolyte disturbances.

An underlying organic cause of constipation must be ruled out before continuous daily use. Caution may also be required if a specific formulation contains excipients such as aspartame (for Phenylketonuria) or sorbitol (for Fructose Intolerance).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Casenlax (Macrogol 4000) is an inert medicine that is not absorbed into the bloodstream. Therefore, its documented interaction profile is defined by physical effects and pharmacodynamic consequences rather than metabolic processes.

Exposure-Modifying Interactions

The official regulatory profile notes that co-administration with other oral medicines may transiently reduce intestinal absorption. This effect can decrease the systemic exposure and subsequent effectiveness of the co-administered drug. The potential reduction in efficacy is considered most significant for medicines with a narrow therapeutic index, such as Digoxin and certain Antiepileptic Agents. To address this documented risk, the administration of Casenlax should be managed separately in time from other oral medications.

Pharmacodynamic and Physical Constraints

A specific additive pharmacodynamic interaction is noted with Diuretics (Water Tablets). If Casenlax causes diarrhea, co-administration may increase the risk of developing electrolyte disturbances, including hyponaemia and hypokalaemia. Patients with impaired renal or hepatic function and the elderly are identified in regulatory documents as being at a heightened risk for this disturbance.

Furthermore, a physical incompatibility restriction exists for starch-based thickeners. Casenlax must not be mixed with these products, as the combination counteracts the thickening effect and increases the documented hazard of aspiration.

Mechanism of Action

Casenlax, containing macrogol 4000 (polyethylene glycol), is a biologically inert, linear polymer classified as an osmotic agent. Following oral administration, the macrogol 4000 molecules are poorly absorbed across the gastrointestinal mucosa, remaining confined to the intestinal lumen.

The primary biological target is the fluid content within the colon. The compound functions via a physical interaction, forming hydrogen bonds with water molecules. This high-affinity water binding capacity sequesters and retains the administered and endogenous fluid within the colonic lumen.

This molecular interaction increases the luminal osmotic pressure, which prevents the passive reabsorption of water from the chyme. The consequent increase in intraluminal fluid volume modulates the system-level physiological state by hydrating and increasing the mass of the fecal matter. This modification facilitates the transit and subsequent expulsion of colonic contents.

Dosage and Administration Information

Official Administration Guidelines for Casenlax

Casenlax (Macrogol 4000) is administered via the oral route as a powder for solution.

Dosing and Preparation

Age Group Recommended Daily Dose Max Duration (if stated)
Adults 1 to 2 sachets per day Not specified
Children (from 8 years) 1 to 2 sachets per day Maximum of 3 months

Preparation Steps:

  1. Dissolve the entire contents of one sachet in a glass of water, typically 125 ml, immediately before use.
  2. Stir the mixture until the powder is completely dissolved, yielding a clear and transparent solution.

Administration Timing and Schedule

The dosage should be adapted based on the achieved clinical effect, ranging from one sachet every other day up to a maximum of 2 sachets per day. The full daily dose is preferably taken as a single dose in the morning.

  • Missed Dose: If a dose is forgotten, do not take a double dose to compensate. Continue with the regular schedule.
  • Onset of Effect: The therapeutic effect of the medicine typically occurs 24 to 48 hours after administration.

Procedural Notes

Treatment should be gradually discontinued once normal intestinal motility is restored, and may be resumed if constipation recurs. For children from 8 years of age, treatment must not exceed three months. Users are advised that this medicine may delay the absorption of other concomitantly administered oral medicines, potentially reducing their effectiveness.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Casenlax (Macrogol 4000)


Evidence for Chronic Functional Constipation in Adults

The primary evidence base for Macrogol 4000 has been used in research exploring how symptoms change over time in adults dealing with chronic, non-organically caused difficulty passing stools. This research mainly consists of short-term Randomized Controlled Trials (RCTs) against placebo and other osmotic agents. Researchers monitored outcomes related to physical discomfort, such as weekly bowel movement frequency and stool consistency, using recognized symptom scales. Studies conducted during periods of increased symptom activity reported measurements of these key functional measures in the observed populations. Follow-up durations were limited in many primary efficacy trials, and long-term outcomes for persistent use are not fully established.


Evidence for Chronic Functional Constipation in Children

Macrogol 4000 was evaluated in numerous pediatric-specific RCTs and systematic reviews focused on children with chronic functional constipation. Studies examined outcomes reflecting daily functioning, such as stool consistency and sustained frequency of bowel movements. Findings describe patterns observed in the studies regarding changes in chronic symptoms and maintenance of regular bowel activity over several months. Evidence quality varies across studies, and research for this specific formulation (without added electrolytes) is limited regarding long-term comparisons against other Macrogol formulations and lactulose beyond the initial treatment periods.


Evidence for Fecal Impaction Management

Research has explored the use of Macrogol 4000 protocols for the acute symptom of fecal impaction, primarily in children. Researchers examined outcomes describing episodic or acute changes, specifically monitoring the time to achieve successful disimpaction (clearance of the impacted mass). Evidence for the disimpaction indication was often derived from trials embedded within broader chronic constipation research protocols. Comparative evidence is lacking for Macrogol 4000 without electrolytes specifically for disimpaction, and data for this specific use in the adult population are currently insufficient.


What is Still Uncertain About Casenlax Research

Evidence quality varies across studies, and comparative evidence is lacking in some areas, such as robust long-term comparisons against certain other Macrogol formulations. Furthermore, data regarding the effects of Macrogol 4000 when used continuously for periods extending beyond one year are currently insufficient, as long-term outcomes are not fully established by prospective trials. The subgroup findings are uncertain for many adults with complex, co-existing health issues, meaning research highlights what is known for the general population but not research findings for all patient types.

Key Studies & References

  1. Use of polyethylene glycol in functional constipation and fecal impaction
  2. Polyethylene Glycol - StatPearls (NIH Bookshelf)
  3. Public Assessment Report Scientific discussion Omnilax (macrogol) (Supporting Regulatory Data for Macrogol 4000)

Frequently Asked Questions (FAQ)

Common questions about Casenlax (FAQ)


Q: Is Casenlax considered a prescription drug or is it available over the counter?

According to the official regulatory status, Macrogol 4000 formulations like Casenlax are commonly classified for over-the-counter (OTC) availability in many regions. However, this is always subject to the specific national regulatory status of the product and its local labeling.


Q: What does 'functional constipation' mean when talking about Casenlax?

Functional constipation is the condition that Casenlax is approved to treat. Official documents generally describe it as chronic difficulty passing stools that is not caused by an underlying organic or structural issue in the body.


Q: Is it possible to take Casenlax long-term?

Official administration guidelines indicate that treatment duration for children aged 8 and over should not exceed three months due to limited long-term clinical data. While a maximum duration for adults is generally not specified in these documents, the availability of safety data for continuous use extending beyond one year is generally limited in current research.


Q: Are there any known issues with taking Casenlax every day, or does it lose its effectiveness over time?

Regulatory documents indicate that Casenlax does not typically lead to dependency or a loss of effectiveness (tolerance or tachyphylaxis) over time. Regulatory documents note the medicine’s action is defined as physical and local, distinguishing it from stimulant laxatives, which may cause dependency.


Q: Why do some people say Casenlax is gentler than other laxatives?

The perception of Casenlax being gentler stems from its official classification as an osmotic laxative. The medicine works by retaining water in the bowel via a physical mechanism, rather than by stimulating the gut wall muscles.


Q: Is Casenlax the same as Miralax or Movicol, and are there different brand names for the same active ingredient?

The active ingredient in Casenlax is Macrogol 4000 (Polyethylene Glycol). This active ingredient is available under many different trade names globally, and other products like Miralax and Movicol also contain Macrogol or a related polyethylene glycol as their active ingredient.


Q: Are there different dosages of Casenlax available?

Official labeling confirms the medicine is supplied as a powder in single sachets. While the recommended dosage is managed by adjusting the number of sachets taken per day, the contents of each sachet usually contain a single, standardized approved strength.


Q: Is it common to feel bloated or gassy when first starting Casenlax?

Official safety information documents abdominal distension (bloating) and flatulence (passing gas) as common side effects, affecting up to 1 in 10 people. These gastrointestinal effects are noted as generally transient, meaning they are temporary and may improve with continued use.


Q: Does Casenlax interact with any common vitamins or mineral supplements?

The official interaction profile states that co-administration with other oral medicines may transiently reduce intestinal absorption. This general precaution applies to all oral medications taken at the same time and may potentially include vitamins and mineral supplements.


Q: Are there any foods or drinks that should be avoided while taking Casenlax?

Regulatory documents include a physical incompatibility restriction that warns against mixing Casenlax with starch-based thickeners, as this counteracts the thickening effect. No other specific food groups or drinks are generally advised to be avoided.


Q: Do official documents mention what to do if the expected effect of Casenlax doesn't happen?

If the expected effect (relief of stools within 24 to 48 hours) does not occur, official documentation indicates that the dose may be adapted based on the observed clinical effect, up to the maximum recommended daily amount.


Q: Why is Casenlax available in a powder form?

The active ingredient, Macrogol 4000, is a highly soluble polymer supplied in powder form. This formulation ensures its stability and allows it to be easily dissolved in a liquid vehicle for optimal osmotic action within the gut.


Q: Does Casenlax have a taste or smell when mixed with water?

Regulatory information describes the product as a powder that forms a clear solution. Some formulations are noted to contain a sweetener or flavouring, while others are described as being without taste or smell.


Q: Is Casenlax suitable for people with diabetes?

Regulatory documents confirm that Casenlax typically contains an insignificant amount of sugar or polyols. This formulation feature means it may be suitable for patients managing blood sugar levels or those on a galactose-free diet.


Q: What are the signs of a possible allergic reaction to Casenlax?

Serious adverse reactions of hypersensitivity (such as anaphylactic shock and angioedema) are documented as very rare. These reactions are typically associated with signs like rash, swelling of the face, lips, tongue, or throat, or difficulty breathing.


Q: Does Casenlax contain any gluten, lactose, or sugar?

Official labeling describes the composition, and many Macrogol 4000 formulations are created without excipients like gluten or lactose. The composition should be confirmed by reviewing the specific excipient list for the formulation of Casenlax being used.


Q: Why is Casenlax not recommended for people with an intestinal obstruction?

The medicine is strictly contraindicated in cases of confirmed or suspected intestinal obstruction (ileus), toxic megacolon, or perforation of the digestive tract. This is because its water-retaining mechanism may increase the risk of these serious conditions.


Q: Are there any common reasons patients stop taking Casenlax?

The most common documented adverse reactions affecting up to 1 in 10 people, such as abdominal pain, diarrhea, and bloating, are often the reasons for dose reduction or discontinuation. These gastrointestinal effects are usually transient.


Q: Can Casenlax be used temporarily for occasional constipation?

While the primary approved indication is for chronic functional constipation, official guidance notes that treatment should be a temporary adjunct and can be resumed if constipation recurs. This suggests its suitability for non-continuous use as needed.


Q: Is it typical for Casenlax to cause a change in stool color or consistency?

The medicine is designed to increase the water content and volume of the stool mass to achieve softening, which is the desired change in consistency. Official documents do not typically list a change in stool color as a documented side effect.


Q: Can Casenlax be split or dissolved in a smaller amount of liquid?

Official preparation instructions specify dissolving the entire contents of one sachet in a typical amount of water immediately before use. Administration guidelines do not support taking less than the entire sachet contents or dissolving it in a smaller amount of liquid than specified.

How should Casenlax be stored and disposed of?

Storage Conditions

Casenlax (Macrogol 4000) powder for oral solution does not require any special temperature storage conditions.

To ensure stability and protect the powder from moisture, the medicine must be stored in the original package and should not be used past the expiration date. The labeled shelf-life for the unopened product is three years.

Child-Safety Storage: The medicine must be kept out of the sight and reach of children.


Disposal Instructions

Official regulatory guidelines for unused or expired Casenlax state that it must not be thrown away via wastewater or household waste.

Patients are instructed to ask a pharmacist for the proper method to discard the medicine that is no longer needed. The regulatory documentation indicates no special requirements for the disposal of general waste materials from the medicinal product itself.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Casenlax found in:

A-Z Index: